Andrx Corp

Andrx — Merger or Acquisition (March 2006)

14 slides from Andrx's merger presentation, Mar 14, 2006

  1. Slide 1: Andrx Acquisition Conference Call & Webcast

    Slide 1: Andrx Acquisition Conference Call & Webcast

    Conference Call & Webcast Corona, CA March 13, 2006 Andrx Acquisition

  2. Slide 2: Agenda

    Slide 2: Agenda

    Agenda Allen Chao, Ph.D., Chairman and CEO Transaction overview and rationale Charles Slacik, EVP and Chief Financial Officer Financing Q&A

  3. Slide 3: Note Regarding Projections and Forward-Looking Statements

    Slide 3: Note Regarding Projections and Forward-Looking Statements

    Note Regarding Projections and Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this presentation that address activities, events or developments that Watson and Andrx expect, bel

  4. Slide 4: Additional Information about the Transaction and Where to Find It

    Slide 4: Additional Information about the Transaction and Where to Find It

    Additional Information about the Transaction and Where to Find It This conference call may be deemed to be solicitation material in respect of the proposed merger of Watson and Andrx. In connection with the proposed merger, Andrx will file a proxy statement with the U.S. Securities and Exchange Comm

  5. Slide 5: Allen Chao, Ph.D. Chairman and CEO

    Slide 5: Allen Chao, Ph.D. Chairman and CEO

    Allen Chao, Ph.D. Chairman and CEO

  6. Slide 6: Transaction Overview

    Slide 6: Transaction Overview

    Transaction Overview $1.9B all cash transaction Watson to acquire Andrx's common stock at $25.00 per share Expected to be accretive beginning in 2007 Closing expected in 3Q 2006 Closing subject to regulatory approvals, Andrx shareholder vote and other customary closing conditions

  7. Slide 7: Strategic Rationale

    Slide 7: Strategic Rationale

    Strategic Rationale Will strengthen Watson's capabilities in sustained- release technologies Expected increased breadth of Watson's product offerings To increase the depth of Watson's pipeline >60 ANDAs on a combined basis Complements Watson's pipeline Anda to provide financial stability and solid c

  8. Slide 8: Andrx Attributes

    Slide 8: Andrx Attributes

    Andrx Attributes Anda Cartia XT (diltiazem HCl) Diltia XT (diltiazem HCl) Taztia XT (diltiazem HCl) Metformin ER Pipeline: 30 ANDAs gToprol XL gCardizem LA gPrilosec gConcerta gBiaxin XL filmtab Generics Andrx Therapeutics 15 Drug Delivery Technologies ACTOSplus met formin XR Altoprev Fortamet Solid

  9. Slide 9: Synergies

    Slide 9: Synergies

    Synergies Corporate SG&A Overlapping projects in development

  10. Slide 10: Charles Slacik EVP & Chief Financial Officer

    Slide 10: Charles Slacik EVP & Chief Financial Officer

    Charles Slacik EVP & Chief Financial Officer

  11. Slide 11: Financing

    Slide 11: Financing

    Financing $1.9 billion cash acquisition Financed from Watson cash reserves and committed bank financing Merger approved by boards of directors of both Watson and Andrx

  12. Slide 12: Financial Conclusions

    Slide 12: Financial Conclusions

    Financial Conclusions Expected to be accretive to earnings beginning in 2007 Anticipate no change in BBB rating expected Financial flexibility for future product acquisitions

  13. Slide 13: Allen Chao, Ph.D. Chairman and CEO

    Slide 13: Allen Chao, Ph.D. Chairman and CEO

    Allen Chao, Ph.D. Chairman and CEO

  14. Slide 14: A Stronger Watson; Well Positioned for Growth

    Slide 14: A Stronger Watson; Well Positioned for Growth

    A Stronger Watson; Well Positioned for Growth Pipeline Will strengthen pipeline of specialty products Will have over 60 ANDAs combined Technologies Will strengthen technology base with sustained release capabilities Sales and Marketing Will broaden product offering for our customers API/ Cost of Goo

Source: SEC EDGAR · DEFA14A filed Mar 14, 2006

More decks from Andrx Corp